

CITATION REPORT

List of articles citing

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy

DOI: 10.1177/1758834015616934

Therapeutic Advances in Medical Oncology, 2016, 8, 48-56.

Source: <https://exaly.com/paper-pdf/65668287/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
214	The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma. 2016 , 175, 1210-1220		21
213	Oncolytic immunotherapy: an emerging new modality for the treatment of cancer. 2016 , 27, 1805-8		6
212	Role of Yes-associated protein in cancer: An update. 2016 , 12, 2277-2282		28
211	BH3-only protein Bim predicts advanced stage of cutaneous melanoma. 2016 , 30, 1926-1929		2
210	Formaldehyde solutions in simulated sweat increase human melanoma but not normal human keratinocyte cells proliferation. 2016 , 37, 106-112		9
209	16th ISoP Annual Meeting & Pharmacovigilance for Safer Tomorrow, Agra, India 16-19 October, 2016 : ABSTRACTS. 2016 , 39, 989-1042		1
208	BRAF V600E mutation in hairy cell leukemia: from bench to bedside. 2016 , 128, 1918-1927		57
207	Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation. 2016 , 11, 417-28		29
206	miR-137 suppresses tumor growth of malignant melanoma by targeting aurora kinase A. 2016 , 475, 251-6		14
205	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. 2017 , 7, 302-321		80
204	Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches. 2017 , 7, 5-19		193
203	Targeting protein kinase-b3 (akt3) signaling in melanoma. 2017 , 21, 273-290		13
202	Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors. 2017 , 77, 1599-1610		58
201	Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells. 2017 , 1861, 2980-2992		22
200	Identification of ACA-28, a 1Sacetoxychavicol acetate analogue compound, as a novel modulator of ERK MAPK signaling, which preferentially kills human melanoma cells. 2017 , 22, 608-618		11
199	Mucosal melanoma of the upper airways tract mucosal melanoma: A systematic review with meta-analyses of treatment. 2017 , 39, 819-825		24
198	Advances in potential targeted therapies for Erdheim-Chester disease. 2017 , 1-8		4

197	Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on Melanoma Lines with Vemurafenib. 2017 , 5, 582-593	14
196	A review of binimetinib for the treatment of mutant cutaneous melanoma. 2017 , 13, 1755-1766	24
195	Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma. 2017 , 51, 675-681	20
194	Limits to Precision Cancer Medicine. 2017 , 376, 96-7	13
193	Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging. 2017 , 7, 8215	7
192	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. 2017 , 23, 6054-6061	48
191	BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. 2017 , 23, 6203-6214	22
190	BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines. 2017 , 404, 70-78	6
189	p53 loss does not permit escape from Braf-induced senescence in a mouse model of lung cancer. 2017 , 36, 6325-6335	7
188	The tumour suppressor, miR-137, inhibits malignant melanoma migration by targetting the TBX3 transcription factor. 2017 , 405, 111-119	31
187	A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors. 2017 , 9, 1495-1506	8
186	Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. 2017 , 27, 545-557	4
185	Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. 2017 , 30, 1338-1366	27
184	Risk of Ophthalmic Adverse Effects in Patients Treated with MEK Inhibitors: A Systematic Review and Meta-Analysis. 2017 , 57, 60-69	10
183	Histopathologic diagnosis of brain metastases: current trends in management and future considerations. 2017 , 34, 8-19	15
182	Patients' Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers. 2017 , 8, 683	8
181	Erdheim-Chester Disease with No Skeletal Bone Involvement and Massive Weight Loss. 2017 , 2017, 3862052	5
180	Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model. 2017 , 11, 70	22

179	Aktuelle Immuntherapien des malignen Melanoms. 2017 , 20, 16-20	
178	BRAF inhibitors: resistance and the promise of combination treatments for melanoma. 2017 , 8, 78174-78192	54
177	Genomics of Hairy Cell Leukemia. 2017 , 35, 1002-1010	42
176	Molecular Tests for the Choice of Cancer Therapy. 2017 , 23, 4794-4806	6
175	[Current aspects in the prognosis of advanced melanoma]. 2018 , 69, 249-259	
174	Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. 2018 , 33, 890-904.e5	284
173	BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. 2018 , 66, 82-94	66
172	Predictive approaches for drug combination discovery in cancer. 2018 , 19, 263-276	41
171	HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. 2018 , 142, 1926-1937	34
170	Design and synthesis of novel thiobarbituric acid derivatives targeting both wild-type and BRAF-mutated melanoma cells. 2018 , 143, 1919-1930	11
169	Early Phase Cancer Immunotherapy. 2018 ,	1
168	Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials. 2018 , 243-280	
167	Aktuelle Immuntherapien des malignen Melanoms. 2018 , 21, 44-51	
166	Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. 2018 , 11, 9081-9089	30
165	A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells. 2018 , 17, 145	37
164	Recent advances in understanding and managing hairy cell leukemia. 2018 , 7,	2
163	Treatments That Block Proteins Involved in Cell Communication. 2018 , 65-109	
162	Aktuelle Immuntherapien des malignen Melanoms. 2018 , 34, 32-38	

161	Pseudotime Dynamics in Melanoma Single-Cell Transcriptomes Reveals Different Mechanisms of Tumor Progression. 2018 , 7,	9
160	Mechanisms and Therapy for Cancer Metastasis to the Brain. 2018 , 8, 161	72
159	Targeted Treatments for Common Solid Tumors. 2018 , 187-257	
158	Subclinical granulomas in benign skin lesions heralding the onset of and inhibitor-associated granulomatous dermatitis in a patient with metastatic melanoma. 2018 , 4, 722-724	8
157	Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment. 2018 , 1, 29-48	49
156	BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation. 2019 , 138, 105039	26
155	Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta-analysis and systematic review. 2019 , 8, 5414-5424	12
154	Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment. 2019 , 309, 231-243	10
153	ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma. 2019 , 18, 1637-1648	7
152	Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment. 2019 , 7,	
151	Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting. 2019 , 19, 1025	3
150	Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers. 2019 , 10, 5143	9
149	Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. 2019 , 7, 4	12
148	Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma. 2019 , 10, 443	15
147	New treatment options in hairy cell leukemia with focus on BRAF inhibitors. 2019 , 37 Suppl 1, 30-37	15
146	A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases. 2019 , 12, 951-958	6
145	Analysis of the Human Kinome and Phosphatome by Mass Cytometry Reveals Overexpression-Induced Effects on Cancer-Related Signaling. 2019 , 74, 1086-1102.e5	18
144	Novel Small Molecule MEK Inhibitor URML-3881 Enhances Cisplatin Sensitivity in Clear Cell Ovarian Cancer. 2019 , 12, 917-924	4

143	Moxetumomab pasudotox for the treatment of hairy cell leukemia. 2019 , 19, 501-508	16
142	Musings on Melanoma. 2019 , 41, 791-793	
141	Molecular Diagnostics in Melanoma: An Update. 2019 , 73-88	
140	Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. 2019 , 175, 339-351	10
139	Quantifying Drug Combination Synergy along Potency and Efficacy Axes. 2019 , 8, 97-108.e16	67
138	Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine. 2019 , 27, 3869-3875	
137	Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma. 2019 , 74, 43-48	11
136	BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. 2019 , 25, 2783-2794	18
135	Many ways to resistance: How melanoma cells evade targeted therapies. 2019 , 1871, 313-322	92
134	Reverse Translation to Support Efficient Drug Target Selection and Stratified Medicine. 2019 , 153-177	
133	Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review. 2019 , 11,	15
132	A multidimensional impedance platform for the real-time analysis of single and combination drug pharmacology in patient-derived viable melanoma models. 2019 , 123, 185-194	9
131	Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. 2019 , 104, 576-586	28
130	Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC. 2020 , 27, 293-300	28
129	Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer. 2020 , 121, 1156-1168	13
128	Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy. 2020 , 44, 1283-1293	5
127	Subversion of Ras Small GTPases in Cutaneous Melanoma Aggressiveness. 2020 , 8, 575223	3
126	Therapeutic potential of polypeptide-based conjugates: Rational design and analytical tools that can boost clinical translation. 2020 , 160, 136-169	18

125	Strategies in DNA vaccine for melanoma cancer. 2021 , 34, 869-891	3
124	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. 2020 , 6, 1256-1264	27
123	Overcoming Immune Evasion in Melanoma. 2020 , 21,	29
122	Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology. 2020 , 140, 2319-2325.e1	0
121	Investigating the Effects of Shikonin, Deoxyshikonin, and (E)-Dimethylacryl)Shikonin on Melanoma Cell Lines. 2020 , 15, 1934578X2092232	0
120	Sinonasal Malignant Melanoma. 2020 , 84, 185-196	4
119	Successful BRAF/MEK inhibition in a patient with -mutated extrapancreatic acinar cell carcinoma. 2020 , 6,	4
118	Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma. 2020 , 8,	3
117	Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders. 2020 , 63, 15883-15905	10
116	BRAF mutation and its inhibitors in sarcoma treatment. 2020 , 9, 4881-4896	11
115	Stratification and prediction of drug synergy based on target functional similarity. 2020 , 6, 16	14
114	Loss of prdm1a accelerates melanoma onset and progression. 2020 , 59, 1052-1063	4
113	Impact of the Protein Data Bank on antineoplastic approvals. 2020 , 25, 837-850	12
112	Current Advances in the Treatment of BRAF-Mutant Melanoma. 2020 , 12,	55
111	Targeted melanoma radiotherapy using ultrasmall Lu-labeled α -melanocyte stimulating hormone-functionalized core-shell silica nanoparticles. 2020 , 241, 119858	20
110	Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade. 2020 , 21,	28
109	Adult Craniopharyngiomas. 2020 ,	0
108	Pulmonary Langerhans Cell Histiocytosis. 2020 , 41, 269-279	6

107	The MEK/ERK Network as a Therapeutic Target in Human Cancer. 2021 , 19, 361-374	15
106	Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients. 2021 , 250-251, 25-35	2
105	Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo. 2021 , 3, vdab020	2
104	Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges. 2021 , 23, e6	2
103	Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. 2021 , 11,	3
102	Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600 mutated malignant melanomas. 2021 , 11, 1834	7
101	Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?. 2021 , 77, 67-82	5
100	ERK and mTORC1 Inhibitors Enhance the Anti-Cancer Capacity of the Octpep-1 Venom-Derived Peptide in Melanoma BRAF(V600E) Mutations. 2021 , 13,	2
99	Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. 2020 , 11, 629722	15
98	Druggable genome and precision medicine in cancer: current challenges. 2021 , 288, 6142-6158	6
97	Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. 2021 , 34, 108870	3
96	V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. 2021 , 20, 1072-1079	3
95	Activable Multi-Modal Nanoprobes for Imaging Diagnosis and Therapy of Tumors. 2020 , 8, 572471	2
94	Novel topical and transdermal delivery of colchicine with chitosan based biocomposite nanofibrous system; formulation, optimization, characterization, ex vivo skin deposition/permeation, and anti-melanoma evaluation. 2021 , 263, 124381	7
93	Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need. 2021 , 23, 84	2
92	Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations. 2021 , 13,	2
91	Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition. 2021 , 141, 1317-1324.e1	5
90	Artificial intelligence in early drug discovery enabling precision medicine. 2021 , 16, 991-1007	6

89	Overcoming resistance to BRAF inhibition in melanoma by deciphering and targeting personalized protein network alterations. 2021 , 5, 50	4
88	Advances in the discovery and development of melanoma drug therapies. 2021 , 16, 1319-1347	0
87	Recognition, Staging, and Management of Melanoma. 2021 , 105, 643-661	1
86	A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer. 2021 , 21, 923	2
85	Unraveling the Relevance of ARL GTPases in Cutaneous Melanoma Prognosis through Integrated Bioinformatics Analysis. 2021 , 22,	0
84	Systemic Therapy in Thyroid Cancer.. 2022 , 13, 68-80	
83	Target Enrichment Enhances the Sensitivity of Sanger Sequencing for BRAF V600 Mutation Detection.	
82	Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. 2021 ,	11
81	Artificial intelligence and machine learning methods in predicting anti-cancer drug combination effects. 2021 , 22,	2
80	The Functional Role of Long Non-Coding RNAs in Melanoma. 2021 , 13,	1
79	Adjuvant treatment in patients with melanoma: The planning of scanning. 2021 , 157, 306-307	0
78	New insights into Raf regulation from structural analyses. 2021 , 71, 223-231	2
77	Assessing the Educational and Supportive Care Needs of Canadian Metastatic Melanoma Patients and Survivors Attending an Outpatient Clinic. 2021 , 8, 23743735211033126	0
76	Drug Resistance in Skin Diseases. 2021 , 197-234	
75	The Impact of Olive Oil Compounds on the Metabolic Reprogramming of Cutaneous Melanoma Cell Models. 2021 , 26,	2
74	Immunotherapy against esophageal primary amelanotic malignant melanoma relapse. 2021 , 2021, rjab393	0
73	Melanoma Metabolism: Cell Survival and Resistance to Therapy. 2020 , 1219, 203-223	9
72	Loss of prdm1a accelerates melanoma onset and progression.	2

71	The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma. 2018 , 3,	17
70	Detection of , , , , and mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis. 2017 , 8, 52304-52320	14
69	Targeting the oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib. 2017 , 8, 113472-113493	10
68	Melanoma patients with additional primary cancers: a single-center retrospective analysis. 2019 , 10, 3373-3384	1
67	SnapshotDx Quiz: November 2021. 2021 , 141, e131-e135	
66	Malignant melanoma and new options of treatment. 2016 , 10, 256-262	
65	A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination.	
64	Stratification and prediction of drug synergy based on target functional similarity.	
63	Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma. 2019 , 14, 203-225	0
62	BRAF Mutant Metastatik Melanomda Dabrafenib-trametinib Kombinasyon Tedavisi Sonrasında Gelişen Yan Etki Yüzerlimi: İki Olgu Sunumuyla Birlikte Literatür Derlemesi.	
61	How a little logic could have corrected long-held misbeliefs. 2020 , 225-270	
60	Molecular Targets in Craniopharyngioma. 2020 , 209-221	1
59	The BRD9/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling and Inducing Apoptosis. 2021 , 13,	2
58	Overcoming Resistance to BRAFV600E Inhibition in Melanoma by Deciphering and Targeting Personalized Protein Network Alterations.	
57	BRAF in malignant melanoma progression and metastasis: potentials and challenges. 2020 , 10, 1103-1114	7
56	Smad7 suppresses melanoma lung metastasis by impairing Tregs migration to the tumor microenvironment. 2021 , 13, 719-731	
55	Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice. 2021 , 14, 5345-5352	1
54	KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. 2021 ,	1

53	Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation. 2021 , 6, 100303	1
52	Prospects for Targeted Kinase Inhibition in Cancer: Neurofibromatosis Type 1-Related Neoplasia. 2021 ,	
51	Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre.. 2022 ,	0
50	NRF2 and Key Transcriptional Targets in Melanoma Redox Manipulation.. 2022 , 14,	1
49	High-Content Screening Pipeline for Natural Products Targeting Oncogenic Signaling in Melanoma.. 2022 ,	0
48	The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K-Akt Pathways.. 2022 , 14,	1
47	Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation.. 2022 , 10781552221091282	0
46	Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs.. 2022 , 13, 301	0
45	PPP6C, a serine-threonine phosphatase, regulates melanocyte differentiation and contributes to melanoma tumorigenesis through modulation of MITF activity.. 2022 , 12, 5573	1
44	Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: A real-world study. 2021 ,	2
43	Magnetic nanoparticles in theranostics of malignant melanoma.. 2021 , 11, 127	1
42	Methylation Markers in Cutaneous Melanoma: Unravelling the Potential Utility of Their Tracking by Liquid Biopsy.. 2021 , 13,	1
41	Revisiting the melanomagenic pathways and current therapeutic approaches.. 2022 , 1	0
40	Data_Sheet_1.PDF. 2019 ,	
39	Roles for GADD45 in Development and Cancer.. 2022 , 1360, 23-39	0
38	Translating Molecules into Imaging—the Development of New PET Tracers for Patients with Melanoma. 2022 , 12, 1116	1
37	Nuclear focal adhesion kinase induces APC/C activator protein CDH1-mediated cyclin-dependent kinase4/6 degradation and inhibits melanoma proliferation.. 2022 , 102013	
36	The Dark Side of Melanin Secretion in Cutaneous Melanoma Aggressiveness. 2022 , 12,	2

35	Primary intracranial malignant melanomas in solitary type: a tertiary center experience.. 2022 , 101, 37-46	
34	The Current State of Precision Medicine and Targeted-Cancer Therapies: Where Are We?. 2022 , 119-200	
33	Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. 2022 , 23, 5731	1
32	Wild-type IDH1 inhibition enhances chemotherapy response in melanoma.	0
31	Scrambling for BRAF Mutation Status in Patients With Melanoma: Is It Really Necessary to Initiate Treatment?.	0
30	Genetic silencing of AKT induces melanoma cell death.	
29	Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies. 2022 , 14, 3779	1
28	Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma. 2022 ,	2
27	Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma. 13,	0
26	The current state of the art and future trends in RAS-targeted cancer therapies.	6
25	Immunotherapy-Associated Uveitis.	0
24	Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance. 12,	0
23	Wild-type IDH1 inhibition enhances chemotherapy response in melanoma. 2022 , 41,	0
22	Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies. 2022 , 23, 1428-1442	1
21	Novel treatments in optic pathway gliomas. 2,	0
20	Identification of novel natural drug candidates against BRAF mutated carcinoma; An integrative in-silico structure-based pharmacophore modeling and virtual screening process. 10,	1
19	CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma. 2022 , 13,	0
18	Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines.	0

17	In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I. 2022 , 23, 12984	0
16	Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?. 2022 , 14, 5184	0
15	Options of Therapeutics and Novel Delivery Systems of Drugs for the Treatment of Melanoma.	1
14	Clinical Trials in Melanoma. 2022 ,	1
13	RAS: Circuitry and therapeutic targeting. 2023 , 101, 110505	0
12	Bilateral multifocal central serous retinopathy due to management of metastatic melanoma with BRAF MEK inhibitors: Case report. 2023 , 9, 100208	0
11	Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping. 2022 ,	0
10	Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update. 13,	0
9	Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies. 9,	0
8	Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines. 2023 , 8,	0
7	Establishment of a BRAF V595E -mutant canine prostate cancer cell line and the antitumor effects of MEK inhibitors against canine prostate cancer.	0
6	Synergistic effects of complex drug combinations in colorectal cancer cells predicted by logical modelling. 3,	1
5	Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant. 2023 , 28, 654-663	0
4	Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases. 2023 , 15, 1884	0
3	Epidemiology of Melanoma.	0
2	Diffuse Cystic Lung Disease. 2023 , 353-368	0
1	Quality by design (QbD) abetted development of pioglitazone incorporated liposomes-loaded hyaluronic acid-based in situ hydrogel for the management of melanoma. 2023 , 84, 104453	0